clinical trial · NCT04103450
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
Urovant Sciences GmbH·phase3·completed·n = 276
Overactive BladderVibegron
brief summary
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment in Study URO-901-3005 (NCT03902080).
started
Sep 19, 2019
primary completion
Jul 29, 2022
completion
Jul 29, 2022
last updated
Aug 21, 2024
official title
A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol